My MP wrote to Andrew Dillon, chief exec NICE. She has just forwarded his reply. One paragraph seems to point very clearly to the financial aspect of all this.
'When making their recommendations our independent Appraisal Committee concluded that although the evidence was of poor quality, dasatinib and nilotinib can be considered a clinically effective treatment of CML in people with imatinib resistance and/or intolerance. However, the uncertainty in the estimates concerning the clinical effectivness together with the exceptionally high acquisition costs of these drugs means they cannot be regarded as an appropriate use of NHS resources.'
The letter is signed by Andrew Dillion.
So has one battle been lost? and how do we go on to fight the war?
I am sure Sandy will advise what we need to do next in this struggle.
Pennie.